The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial introduction generated substantial gains, the end of its patent opened the door to off-brand competitors, https://royalbookmarking.com/story21610121/viagra-and-pharma-a-precarious-investment